PT-141

Mechanism

Non-selective melanocortin agonist affecting central arousal circuitry.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Desire and arousal research
• Erectile support context
• On-demand dosing

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Reported adverse effects

• Nausea

  Very common (>10%)onset: Within an hourreported reversible

• Facial flushing

  Common (1-10%)onset: Within an hourreported reversible

• Headache

  Common (1-10%)onset: Hoursreported reversible

• Transient blood pressure increase

  Documentedonset: Post-dosereported reversible

Literature on file 11

• human RCT
  Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial (Women's Health 2016, cited 68x) graded on: a randomised trial — “Randomized, Placebo-Controlled Dose-Finding Trial”
• human observational
  Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov. graded on: a synthesis of human studies — “systematic review”
• human RCT
  NCT02333071: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) graded on: a randomised trial — “Randomized, Double-blind, Placebo-controlled, Trial”
• human RCT
  NCT02338960: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) graded on: a randomised trial — “Randomized, Double-blind, Placebo-controlled, Trial”
• human RCT
  NCT01382719: A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder) graded on: a randomised trial — “Randomized, Parallel Group, Dose-finding Trial”
• human RCT
  FDA approval NDA210557 graded on: an FDA approval (NDA210557), which requires adequate and well-controlled human investigations — “NDA210557”

Not graded

5 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics & Gynecology 2019, cited 133x)
• not graded
  The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives.
• not graded
  FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
• not graded
  Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
• not graded
  Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.

Identity

PubChem CID 9941379 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 9941379, the identifier on this record.

Molecular weight

1025.2

Molecular formula

C50H68N14O10

CAS number

189691-06-3

PubChem CID

9941379

InChI key

FFHBJDQSGDNCIV-MFVUMRCOSA-N

Sequence

XDHFRWK

SMILES

CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC2=CN=CN2)CC3=CC=CC=C3)CCCN=C(N)N)CC4=CNC5=CC=CC=C54)C(=O)O)NC(=O)C

InChI

InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1

Classified as

Melanocortin Receptor Agonismmechanism

A record listing only melanocortin agonism with no receptor subtype is underspecified. Pigmentation, appetite and arousal come from different receptors, so a claim graded for one says nothing about the others.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Also called

• PT-141
• Bremelanotide (PT-141)

Listed prices 6

What 6 shops we track listed for PT-141, read from their own public catalogues on 2026-08-12. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record